Glaukos Corporation announced that the U.S. Centers for Medicare and Medicaid Services’ (CMS) permanent J-code for its newly launched iDose TR (travoprost intracameral implant) 75 mcg has officially been activated.
Let’s begin with the iDose TR.
The iDose TR is a biocompatible titanium implant consisting of a proprietary, preservative-free formulation of (75 mcg) travoprost that’s pre-loaded in a single-dose inserter and placed within the trabecular meshwork until is anchored securely in the sclera.
- Its intended purpose: To be administered during micro-invasive glaucoma surgeries (MIGS).
As a bonus: The intraocular pressure (IOP)-lowering effects of travoprost (a prostaglandin analog), as well as its mechanism of action, are unique—see here to learn why.
And the implant’s indication?
The iDose TR was approved by the FDA in December 2023 for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
The duration of its effects: It’s intended to continuously release the travoprost for at least 1 year.
- Click here and here for supporting clinical data.
- Its prescribing information (PI) includes more details.
It’s currently available in the US, right?
Correct! The device was commercially launched to the U.S. market in March 2024.
Talk about this J-Code
Issued by the Healthcare Common Procedure Coding System (HCPCS), a J-code is a permanent reimbursement designation issued as a HCPCS Level II code for non-orally administered drugs and other medical devices.
- Note: HCPCS standardizes claims for medical services and supplies.
What does this specific code indicate?
One of three major codes—including C-codes (C1713 - C9899) for outpatient prospective patient system and V-codes (V2020 - V2799) for vision services— the J-code (J0120 - J8999) refers to drugs administered via routes that exclude oral methods.
Who they’re used by: The U.S. government,commercial payers, and healthcare providers when submitting claims.
- Why: Essentially, to simplify and facilitate the billing and reimbursement process for medical providers’ products and services.
And in this particular case?
The iDose TR’s new code is expected to help simplify coverage across the U.S., as well as to ensure both consistent reimbursement and broader patient access of the device.
And this new code is… ?
As we previously reported when the company announced the code back in April 2024: J7355.
The J-code for iDose TR took effect July 1, 2024.